JPMorgan raised the firm’s price target on SpringWorks Therapeutics to $77 from $75 and keeps an Overweight rating on the shares. The analyst updated the company’s model post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
- 3 Best Stocks to Buy Now, 5/3/2024, According to Top Analysts
- SpringWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.18)
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting